ALK and cancer: Patients with ALK-positive cancer (median [IQR] age, 55 [47-67] years) were younger than patients with EGFR-positive (median [IQR] age, 62 [56-69] years) and WT (median [IQR] age, 64 [57-71] years) cancer.